TIM-3

[Frontiers in Immunology] Scientists compared surface receptor expression and cytokine production between peripheral blood NK cells from 90 Type 2 diabetes mellitus patients and 62 age- and sex-matched healthy controls.

[Journal of Clinical Investigation] Scientists showed that human PD-1+Tim-3+ CD8+ tumor-infiltrating lymphocytes upregulated phosphatidylserine, a receptor for Tim-3, and acquire cell surface myeloid markers from antigen presenting cells through transfer of membrane fragments called trogocytosis.

[Nature Immunology] Researchers showed that type 1 interferon regulated coinhibitory receptor expression on human T cells, inducing PD-1/TIM-3/LAG-3 while inhibiting T cell immunoreceptor with immunoglobulin and ITIM domains expression.

[Scientific Reports] Mechanistic insights demonstrated that blockade of the PD-1 axis decreased stem-like marker ALDH and expression of DNA repair genes.

[Translational Oncology] Silencing of TIM-3 shuttled by MV3 cells-derived exosomes improved CD4+ T cell immune function and inhibited macrophage M2 polarization to attenuate the growth and metastasis of melanoma cells.

[Reproductive Sciences] Researchers assessed the correlation between immune infiltration status, chemotherapeutics sensitivity, immune checkpoint proteins, and the signature.